Funder
The work was conducted in the context of a European Commission sponsored joint action, Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE).
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference15 articles.
1. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. [Internet].
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf
. Accessed 23 Jan 2018.
2. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for sibutramine. [Internet].
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500069995.pdf
. Accessed 23 Jan 2018.
3. Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012;50(6):466–78.
4. Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf. 2012;35(5):373–85.
5. Piening S, Reber KC, Wieringa JE, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, et al. Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. Clin Pharmacol Ther. 2012;91(5):838–45.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献